Diagnosis and Treatment Strategies in Patients With NSCLC With or Without EGFR Mutations.
The purpose of this trial is to compare the evolution of patients receiving first line treatment for locally advanced or metastatic lung cancer, taking into account if they were requested or not the EGFR mutation test as part of the diagnosis and treatment strategy. There is no assignment to any particular therapeutic strategy.
Stage IIIB/IV|Non-Small Cell Lung Cancer
Disease free survival, 12 months after the diagnosis of advanced disease|Overall Survival, 12 months after the diagnosis of advanced disease|Number of hospitalizations, 12 months after the diagnosis of advanced disease
Study of cases and controls on diagnosis and treatment strategies in patients with NSCLC with or without EGFR mutations.